Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ardoxyn** is an oral fixed-dose antibacterial and probiotic product marketed by Treatwell Pharma. Each tablet contains doxycycline 100 mg plus lactic acid bacillus. Doxycycline is a broad-spectrum tetracycline antibacterial that binds the bacterial 30S ribosomal subunit and inhibits protein synthesis, producing primarily bacteriostatic activity. Lactic acid bacillus is included as a probiotic adjunct. Treatwell Pharma lists Ardoxyn as a doxycycline 100 mg with lactic acid bacillus tablet in its antibiotic/antibacterial portfolio. ([treatwellpharma.in](https://www.treatwellpharma.in/product-list.php))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ardoxyn.